Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429636 | 0.79 | CYP19A1 (0.38) | KMT2AMAPTHSP90AA1MEN1CYP19A1 | |
| SCHEMBL7197056 | 0.77 | MAPT (0.42) | KMT2AMAPTHSP90AA1MEN1CYP19A1 | |
| SCHEMBL9366536 | 0.77 | CYP19A1 (0.39) | KMT2AMAPTHSP90AA1CYP19A1CYP26A1 | |
| SCHEMBL2830866 | 0.76 | PDE4D (0.39) | KMT2AMAPTHSP90AA1MEN1CYP19A1 | |
| SCHEMBL9747750 | 0.73 | MAPT (0.52) | KMT2AMAPTHSP90AA1MEN1CYP19A1 | |
| SCHEMBL7104933 | 0.73 | MAPT (0.39) | KMT2AMAPTHSP90AA1MEN1CYP19A1 | |
| SCHEMBL10709771 | 0.70 | MAPT (0.43) | KMT2AMAPTHSP90AA1MEN1CYP19A1 | |
| SCHEMBL10361017 | 0.70 | ALDH1A1 (0.46) | KMT2AMAPTHSP90AA1MEN1CYP19A1 | |
| SCHEMBL2825464 | 0.69 | RXFP1 (0.39) | LMNAPOLBALDH1A1 | |
| SCHEMBL9795396 | 0.68 | CYP19A1 (0.49) | KMT2AMAPTHSP90AA1MEN1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937688-B1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-7507729-B2 | for the treatment of cognitive disorders, anxiety, schizophrenia, and Alzheimer's disease; ligands; GABA A alpha 5 receptor inhibitors; 3-bromo-10-chloro-6-(2-oxo-pyrrolidin-1-ylmethyl)-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1937688-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042421-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | GABRA5, GABRA1, GABRA4 | KMT2A 1642/4885MAPT 348/4885HSP90AA1 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.